Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Alex H. Chang"'
Autor:
Linqin Wang, Yuqi Lv, Linghui Zhou, Shenghao Wu, Yuanyuan Zhu, Shan Fu, Shuyi Ding, Ruimin Hong, Mingming Zhang, Hanjing Yu, Alex H. Chang, Guoqing Wei, Yongxian Hu, He Huang
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-5 (2024)
Abstract Although the efficacy of chimeric antigen receptor (CAR)-T cell therapy has been widely demonstrated, its clinical application is hampered by the complexity and fatality of its side effects. Cytokine release syndrome (CRS) is the most common
Externí odkaz:
https://doaj.org/article/bdb3d53ed15b4435adf01dca951dd936
Autor:
Xiaojuan Miao, Yanrong Shuai, Ying Han, Nan Zhang, Yilan Liu, Hao Yao, Xiao Wang, Guangcui He, Dan Chen, Fangyi Fan, Alex H. Chang, Yi Su, Hai Yi
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundExplore the efficacy and safety of donor-derived CLL-1 chimeric antigen receptor T-cell therapy (CAR-T) for relapsed/refractory acute myeloid leukemia (R/R AML) bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT) afte
Externí odkaz:
https://doaj.org/article/f6caff94232f4910805acf488875ce98
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
Autor:
Yinqiang Zhang, Chenggong Li, Mengyi Du, Huiwen Jiang, Wenjing Luo, Lu Tang, Yun Kang, Jia Xu, Zhuolin Wu, Xindi Wang, Zhongpei Huang, Yanlei Zhang, Di Wu, Alex H. Chang, Yu Hu, Heng Mei
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is also expressed on normal T cells, which may cause CAR-T cell fratricide. Donor-derived anti-
Externí odkaz:
https://doaj.org/article/ea04534d0c1a4397a276d5c479f10ccf
Autor:
Yue Tan, Lingling Shan, Liping Zhao, Biping Deng, Zhuojun Ling, Yanlei Zhang, Shuixiu Peng, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Qinlong Zheng, Xiuwen Xu, Zhenglong Tian, Yibing Zhang, Jiecheng Zhang, Alex H. Chang, Xiaoming Feng, Jing Pan
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-15 (2023)
Abstract Background Donor-derived CD7-directed chimeric antigen receptor (CAR) T cells showed feasibility and early efficacy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia (r/r T-ALL), in a previous phase I trial report,
Externí odkaz:
https://doaj.org/article/6ca29d0591dc4071843fdc44398d4480
Autor:
Yongxian Hu, Jingjing Li, Fang Ni, Zhongli Yang, Xiaohua Gui, Zhiwei Bao, Houli Zhao, Guoqing Wei, Yiyun Wang, Mingming Zhang, Ruimin Hong, Linqin Wang, Wenjun Wu, Mohamad Mohty, Arnon Nagler, Alex H. Chang, Marcel R. M. van den Brink, Ming D. Li, He Huang
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/1f651cfe9ca345eab3b62b12e20f0bcd
Autor:
Ying Han, Hao Yao, Guang-cui He, Si-han Lai, Yan Deng, Shan Zhang, Ying He, Yi-song Xiong, Alex H. Chang, Yi Su, Hai Yi
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundAllogeneic hematopoietic stem cell transplantation (allo-HSCT) has cured many patients with malignant hematologic diseases such as mixed phenotype acute leukemia (MPAL), while those relapsing after allo-HSCT still exhibit high mortality, po
Externí odkaz:
https://doaj.org/article/ce9daac7678a4886a79100b091a2c7f6
Autor:
Xueer Xu, Cheng Zu, Mingming Zhang, Pingnan Xiao, Ruimin Hong, Jingjing Feng, Huijun Xu, Jiazhen Cui, Jian Yu, Jimin Shi, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu
Publikováno v:
Cell Transplantation, Vol 32 (2023)
While chimeric antigen receptor (CAR)-T-cell therapy has demonstrated remarkable effectiveness in the treatment of B-cell lymphomas and leukemias, research on T-cell malignancies is still limited. Here, we reported a patient with hepatosplenic γδ T
Externí odkaz:
https://doaj.org/article/89ed10010d0b4e5c94425e704efa0336
Autor:
Yongxian Hu, Jingjing Li, Fang Ni, Zhongli Yang, Xiaohua Gui, Zhiwei Bao, Houli Zhao, Guoqing Wei, Yiyun Wang, Mingming Zhang, Ruimin Hong, Linqin Wang, Wenjun Wu, Mohamad Mohty, Arnon Nagler, Alex H. Chang, Marcel R. M. van den Brink, Ming D. Li, He Huang
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
Abstract Immunotherapy utilizing chimeric antigen receptor T cell (CAR-T) therapy holds promise for hematologic malignancies, however, response rates and associated immune-related adverse effects widely vary among patients. Here we show, by comparing
Externí odkaz:
https://doaj.org/article/1221b288530e46c3908f3a0880c39fde
Autor:
Ying Jiang, Dan Feng, Chun Wang, Yanlei Zhang, Chuxian Zhao, Su LI, Youwen Qin, Alex H. Chang, Jun Zhu
Publikováno v:
HemaSphere, Vol 7, p e76055be (2023)
Externí odkaz:
https://doaj.org/article/c5c799b905644382af9ea04cdc2f7671
Autor:
Qiqi Zhang, Cheng Zu, Ruirui Jing, Youqin Feng, Yanlei Zhang, Mingming Zhang, Yuqi Lv, Jiazhen Cui, Linhui Zhou, Ye Meng, Linqin Wang, Zenan Cen, Alex H. Chang, Yongxian Hu, He Huang
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Background aimsB-cell maturation antigen (BCMA)-targeted chimeric antigen receptor-T cell (CAR-T) therapy is used for refractory or relapsed multiple myeloma (r/r MM). However, CAR-T-related tumor lysis syndrome (TLS) has been observed. We aimed to e
Externí odkaz:
https://doaj.org/article/92fc37151f824a59a59fbee3e7560de5